Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

导出 LinkOut

翻译打印收藏纠错

第一作者： Suneeta,Kumari

第一单位： Psychiatry, Hackensack Meridian Ocean Medical Center, Brick, USA.

作者： Suneeta,Kumari ^[1] ; Hassan A,Chaudhry ^[2] ; Adam,Sagot ^[3] ; Stacy,Doumas ^[1] ; Hussain,Abdullah ^[1] ; Eric,Alcera ^[1] ; Ramon,Solhkhah ^[1] ; Saba,Afzal ^[4]

作者单位： Psychiatry, Hackensack Meridian Ocean Medical Center, Brick, USA. ^[1] Medical School, Medical University of Lublin, Lublin, POL. ^[2] Psychiatry and Behavioral Sciences, Youth Neuroscience Organization, Tbilisi, GEO. ^[3] Psychiatry, Northshore University Health System, Evanston, USA. ^[4]

关键词 esketamine fda approval montgomery-asberg depression rating scale nmda receptor antagonist placebo controlled trials selective serotonin reuptake inhibitor (ssri)suicide and depression suicide prevention treatment-related adverse event treatment-resistant depression

DOI 10.7759/cureus.53987

PMID 38476783

发布时间 2024-03-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cureus

2024年16卷2期

e53987页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus

相似文献

Cureus

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus

相似文献

Cureus

相关期刊

检索历史清除